Simultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype 1
暂无分享,去创建一个
John Sidney | Alessandro Sette | Scott Southwood | V. Pasquetto | J. Sidney | A. Sette | S. Southwood | Valerie Pasquetto
[1] J. Kalil,et al. Influence of HLA class I- and class II-specific monoclonal antibodies on DR-restricted lymphoproliferative responses. I. Unseparated populations of effector cells. , 1983, Journal of immunology.
[2] A. Kumar,et al. Immediate Early and Early Lytic Cycle Proteins Are Frequent Targets of the Epstein-Barr Virus–induced Cytotoxic T Cell Response , 1997, The Journal of experimental medicine.
[3] M F del Guercio,et al. Several HLA alleles share overlapping peptide specificities. , 1995, Journal of immunology.
[4] J. Sidney,et al. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.
[5] C. Bordignon,et al. Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. , 1994, Tissue antigens.
[6] A Sette,et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. , 1996, Journal of immunology.
[7] N. Suciu-Foca,et al. Naturally processed HLA class I bound peptides from c-myc-transfected cells reveal allele-specific motifs. , 1993, Journal of immunology.
[8] J. Sidney,et al. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules. , 1999, Human immunology.
[9] Taku Suto,et al. An automated prediction of MHC class I-binding peptides based on positional scanning with peptide libraries , 2000, Immunogenetics.
[10] J. Sidney,et al. HLA supertypes and supermotifs: a functional perspective on HLA polymorphism. , 1998, Current opinion in immunology.
[11] J. Sidney,et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules , 1993, Cell.
[12] John Sidney,et al. Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..
[13] S. Burrows,et al. Identification of cytotoxic T cell epitopes within Epstein‐Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype‐restricted immune recognition of EBV‐infected cells by LMP1‐specific cytotoxic T lymphocytes , 1998, European journal of immunology.
[14] A Sette,et al. Definition of specific peptide motifs for four major HLA-A alleles. , 1994, Journal of immunology.
[15] D. Moss,et al. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. , 1997, Annual review of immunology.
[16] P. Parham,et al. Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. , 1999, Journal of immunology.
[17] V. Gnau,et al. Peptide motifs of HLA-B58, B60, B61, and B62 molecules , 2004, Immunogenetics.
[18] B. Walker,et al. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. , 1996, The Journal of infectious diseases.
[19] J. Skolnick,et al. Application of an artificial neural network to predict specific class I MHC binding peptide sequences , 1998, Nature Biotechnology.
[20] D. R. Madden,et al. Identification of self peptides bound to purified HLA-B27 , 1991, Nature.
[21] R W Chesnut,et al. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. , 1997, The Journal of clinical investigation.
[22] Alessandro Sette,et al. Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.
[23] S. H. van der Burg,et al. Analogues of CTL epitopes with improved MHC class‐I binding capacity elicit anti‐melanoma CTL recognizing the wild‐type epitope , 1997, International journal of cancer.
[24] Xiping Wei,et al. Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.
[25] Effie W Petersdorf,et al. Nomenclature for factors of the HLA system, 2002. , 2002, Human immunology.
[26] J. Frelinger,et al. Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[27] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[28] M F del Guercio,et al. Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. , 1995, Journal of immunology.
[29] F. Chisari,et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis , 1993, The Journal of experimental medicine.
[30] F. Marincola,et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. , 1996, Journal of immunology.
[31] M. Torres,et al. Nomenclature for factors of the HLA system. , 2011, Bulletin of the World Health Organization.
[32] John Sidney,et al. Measurement of MHC/Peptide Interactions by Gel Filtration , 1999, Current protocols in immunology.
[33] R. Offringa,et al. Differential binding of viral peptides to HLA‐A2 alleles. Implications for human papillomavirus type 16 E7 peptide‐based vaccination against cervical carcinoma , 1999, European journal of immunology.
[34] P. Romero,et al. A peptide encoded by the human MAGE3 gene and presented by HLA-1344 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3 , 2005, Immunogenetics.
[35] John Sidney,et al. Identification of Novel HLA-A2-Restricted Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Epitopes Predicted by the HLA-A2 Supertype Peptide-Binding Motif , 2001, Journal of Virology.
[36] A Sette,et al. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. , 1996, Immunology today.
[37] John Sidney,et al. Two distinct HLA-A*0101-specific submotifs illustrate alternative peptide binding modes , 1997, Immunogenetics.
[38] John Sidney,et al. Definition of the Mamu A*01 Peptide Binding Specificity: Application to the Identification of Wild-Type and Optimized Ligands from Simian Immunodeficiency Virus Regulatory Proteins1 , 2000, The Journal of Immunology.
[39] G Hermanson,et al. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. , 1995, Journal of immunology.
[40] C. Bony,et al. Identification in humans of HPV‐16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA‐B18 and determination of the HLA‐B18‐specific binding motif , 2000, European journal of immunology.
[41] Todd M. Allen,et al. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. , 1998, Journal of immunology.
[42] H. Rammensee,et al. Definition of peptide binding motifs amongst the HLA-A*30 allelic group. , 2000, Tissue antigens.
[43] J. Berzofsky,et al. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[44] J. Sidney,et al. Conserved MHC Class I Peptide Binding Motif Between Humans and Rhesus Macaques1 , 2000, The Journal of Immunology.
[45] A. Sette,et al. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.
[46] C. Bordignon,et al. Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. , 1996, Journal of immunology.
[47] A Sette,et al. Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. , 2001, Human immunology.
[48] K. Parker,et al. Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. , 1995, Biochemistry.
[49] Naoki Abe,et al. Empirical Evaluation of a Dynamic Experiment Design Method for Prediction of MHC Class I-Binding Peptides1 , 2002, The Journal of Immunology.
[50] A Sette,et al. Two complementary methods for predicting peptides binding major histocompatibility complex molecules. , 1997, Journal of molecular biology.
[51] B. Malissen,et al. Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. , 2008, Tissue antigens.
[52] H. Zinszner,et al. Nucleotide sequence of the HLA-A26 class I gene: identification of specific residues and molecular mapping of public HLA class I epitopes. , 1990, Human immunology.
[53] A Sette,et al. Human class I supertypes and CTL repertoires extend to chimpanzees. , 1998, Journal of immunology.
[54] M F del Guercio,et al. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules. , 1996, Journal of immunology.
[55] E. Coligan. Current protocols in immunology , 1991 .
[56] G. Chelvanayagam. A roadmap for HLA-A, HLA-B, and HLA-C peptide binding specificities , 1996, Immunogenetics.
[57] J. Sidney,et al. Characterization of the Peptide-Binding Specificity of Mamu-B*17 and Identification of Mamu-B*17-Restricted Epitopes Derived from Simian Immunodeficiency Virus Proteins1 , 2002, The Journal of Immunology.
[58] A. Sette,et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells , 1998, International journal of cancer.
[59] A. Sette,et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. , 1998, Journal of immunology.
[60] B. Walker,et al. Degenerate and promiscuous recognition by CTL of peptides presented by the MHC class I A3-like superfamily: implications for vaccine development. , 1997, Journal of immunology.
[61] M F del Guercio,et al. Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. , 1996, Human immunology.
[62] J. Berzofsky,et al. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions. , 1998, The Journal of clinical investigation.
[63] P. Flores-Villanueva,et al. Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design. , 2001, Human immunology.
[64] J. Sidney,et al. Identification of Five Different Patr Class I Molecules That Bind HLA Supertype Peptides and Definition of Their Peptide Binding Motifs1 , 2000, The Journal of Immunology.
[65] P. Travers,et al. Prediction of an HLA-B44 binding motif by the alignment of known epitopes and molecular modeling of the antigen binding cleft , 2004, Immunogenetics.
[66] T. Boon,et al. A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes , 1996, European journal of immunology.
[67] P. Coulie,et al. A peptide encoded by human gene MAGE‐3 and presented by HLA‐A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE‐3 , 1994, European journal of immunology.
[68] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[69] K. Parker,et al. Sequence motifs important for peptide binding to the human MHC class I molecule, HLA-A2. , 1992, Journal of immunology.
[70] B. Drénou,et al. QUANTIFICATION AND MOLECULAR ANALYSIS OF PLASMATIC HLA‐BCw MOLECULES WITH A LOCUS B AND Cw HLA SPECIFIC mAb (B1.23.2mAb) , 1995, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.
[71] Todd M. Allen,et al. Gorillas with Spondyloarthropathies Express an MHC Class I Molecule with Only Limited Sequence Similarity to HLA-B27 that Binds Peptides with Arginine at P21 , 2001, The Journal of Immunology.
[72] M. Bonneville,et al. T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis , 1996, The Journal of experimental medicine.
[73] R W Chesnut,et al. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. , 1997, Immunity.
[74] A Sette,et al. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. , 1999, Journal of immunology.